Evidence map›Paper›PMID 35809093›Full record

ArticleVirchows Archiv : an international journal of pathology2022

Crohn's disease may promote inflammation in IgA nephropathy: a case-control study of patients undergoing kidney biopsy.

Minako Akiyama, Kosuke Shimomura, Hiroshi Yoshimoto, Minako Sako, Makoto Kodama, Keiko Abe, Mariko Gunji, Dedong Kang, Takashi Takaki, Yukihiro Wada and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Article
  7. IgA nephropathy associated with Crohn's disease.World journal of methodology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Minako AkiyamaDepartment of Nephrology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Kosuke ShimomuraDepartment of Nephrology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Hiroshi YoshimotoDepartment of Nephrology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Minako SakoDepartment of Inflammatory Bowel Disease (IBD), JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Makoto KodamaDepartment of Pathology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Keiko AbeDepartment of Pathology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan.
Mariko GunjiDepartment of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Dedong KangDepartment of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Takashi TakakiDepartment of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Yukihiro WadaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Masayuki IyodaDepartment of Microbiology and Immunology, Showa University School of Medicine, Tokyo, Japan.
Kazuho HondaDepartment of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. kzhonda@med.showa-u.ac.jp.ORCID http://orcid.org/0000-0003-4179-8832
Showa University · JPTokyo Yamate Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal immunity has been closely associated with the pathogenesis and progression of renal diseases, a relationship known as the "gut-kidney axis." To determine the association between immunoglobulin A nephropathy (IgAN) and Crohn's disease (CD), a clinico-pathological study was performed on patients who had IgAN with CD (CD-IgAN) and without CD (NOS-IgAN). We enrolled 29 patients diagnosed with IgAN via renal biopsy at the Tokyo Yamate Medical Center from 2009 to 2017. The patients were divided into CD-IgAN (n = 18) and NOS-IgAN (n = 11) and evaluated for clinical and pathological findings. IgA subclasses and galactose-deficient IgA1 (Gd-IgA1) were examined via immunohistochemistry using formalin-fixed paraffin-embedded sections from renal biopsy. Our results showed no significant difference in the extent of mesangial IgA subclasses or Gd-IgA1 deposition according to the presence or absence of CD. Pathologically, however, those with CD-IgAN had remarkably higher percentage of global glomerulosclerosis and extent of interstitial fibrosis and tubular atrophy (IF/TA) compared to those with NOS-IgAN. Moreover, the extent of macrophage infiltration in the glomerulus and interstitium was significantly higher in CD-IgAN than in NOS-IgAN. Clinically, the CD-IgAN group had significantly worse responsiveness to steroid treatment compared to the NOS-IgAN group. In conclusion, the similar immunological characteristics of deposited IgA molecules in the glomeruli between the CD-IgAN and NOS-IgAN groups might suggest their etiological similarity. However, a renal pathology showing advanced glomerular and tubulointerstitial sclerosis accompanying increased macrophage infiltration and highly resistant clinical features in patients with CD-IgAN suggests that some pathophysiological factors in CD, including abnormal intestinal immunity, may promote and activate the inflammatory process in IgAN via undetermined mechanisms.

Indexed as

Crohn DiseaseGlomerulonephritis, IGABiopsyCase-Control StudiesFormaldehydeGalactoseHumansImmunoglobulin AInflammationKidneySteroidsFormaldehydeGalactoseImmunoglobulin ASteroidsCrohn’s diseaseGalactose-deficient IgA1IgA nephropathyIgA subclassInflammatory bowel diseaseIntestinal immunity

Identifiers

PMID35809093
PMCPMC9534821
OpenAlexW4284969190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.